Thursday 6-12-2014 Geron Corp (GERN) $GERN opened
Post# of 119
Posted On: 06/12/2014 10:29:44 PM
Thursday 6-12-2014 Geron Corp (GERN) $GERN opened at 3.24 hitting the high price of 3.47 and a day low of 3.05 with a total volume of 47,816,829. GERN had a previous close of 2.60 and has been seeing an average volume of 5,324,530.
Overall Average: 72% Buy
Recent stock forum discussions about GERN http://investorshangout.com/search?q=GERN&...mp;yt0=Go!
Nasdaq stocks posting largest volume increases
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
After Yesterday's Rally of 21.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 12, 4:38PM CDT
Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $3.05 to a high of $3.47. Yesterday, the shares gained 21.1%, which took the trading range above the 3-day high of $2.77 on volume of 47.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Why Geron, Restoration Hardware, and ImmunoGen Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 4:15PM CDT
Today, in contrast to the past couple of days, investors had an absolute smorgasbord of economic data dropped in their laps; and the initial reaction is that they were none too impressed, with the S&P 500 suffering its worst single-day loss in... (full story)
Twitter and Delta are big market movers
AP - Thu Jun 12, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Jun 12, 1:43PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels. (full story)
Why Geron Corporation Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Geron , a clinical-stage biopharmaceutical... (full story)
Why Geron (GERN) Stock is Surging Today
at The Street - Thu Jun 12, 8:59AM CDT
Geron (GERN) surged Thursday after the company announced the FDA had removed a partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). (full story)
Geron Corp. (GERN) Soars: Stock Up 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:39AM CDT
Geron Corporation (GERN) was a big mover last session, as its shares rose over 10% on the day. (full story)
Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 12, 7:26AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation and Arena Pharmaceuticals . Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company... (full story)
Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST
Thomson Reuters ONE - Thu Jun 12, 4:00AM CDT
Menlo Park, Calif., June 12, 2014 - Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. In order to resolve the partial clinical hold, the investigator, Dr. Ayalew Tefferi of Mayo Clinic, Rochester, Minnesota, was required to provide follow-up information regarding reversibility of hepatotoxicity for all patients who received imetelstat in the Myelofibrosis IST. In its letter dated June 11, 2014, the FDA informed the investigator that it had completed the review of his complete response submission and concluded that the Myelofibrosis IST may proceed. (full story)
Stock to Watch: Geron Up 11.3% (GERN)
Comtex SmarTrend(R) - Wed Jun 11, 11:38AM CDT
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 11.3% to $2.62 on 3.1x average daily volume. Thus far today, Geron has traded 7.8 million shares, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (11.3% to the Dow's -0.5%) and outperformed the S&P 500 (11.3% to the S&P's -0.3%) during today's trading. (full story)
This Biotech Stock Could Be the Next Big Short Squeeze
at The Street - Tue Jun 10, 1:38PM CDT
The biotech sector is back in play on Wall Street in a big way, and anyone short the sector has to be feeling nervous (full story)
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron
PR Newswire - Fri May 30, 6:10AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average finished the day 0.39% higher at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, and the index has advanced 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) and Geron Corp. (NASDAQ: GERN). Free technical research on GILD, ARIA, RNN and GERN can be downloaded upon signing up at: (full story)
ViaCyte and Asterias Biotherapeutics Settle Patent Dispute
PR Newswire - Thu May 29, 8:00AM CDT
ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes, announced today that the Company has settled a patent dispute involving certain of the Company's definitive endoderm patents and patent applications. The dispute involved an appeal to the U.S. District Court by Asterias Biotherapeutics, Inc., (as assignee of Geron Corporation), which sought to overturn both decisions by the U.S. Patent and Trademark Office (USPTO) against Geron in its patent interferences. (full story)
Geron to Present at the Jefferies Healthcare Conference
Thomson Reuters ONE - Wed May 28, 6:31AM CDT
MENLO PARK, Calif., May 28, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Jefferies 2014 Global Healthcare Conference in New York. The presentation is scheduled to occur at 10:00 a.m. Eastern Time on Wednesday, June 4th. (full story)
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Tue May 27, 2:15PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long... (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu May 22, 1:33PM CDT
These under-$10 stocks look ready to trade higher from current levels. (full story)
Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
Business Wire - Wed May 21, 8:15AM CDT
Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX) that is developing clinical-stage stem cell therapeutic assets acquired from Geron Corporation, today announced the launch of its new website, www.asteriasbiotherapeutics.com. The website provides information about Asterias, including its core technologies, areas of product development focus, intellectual property portfolio, key publications, SEC filings, and management team. (full story)
Overall Average: 72% Buy
Recent stock forum discussions about GERN http://investorshangout.com/search?q=GERN&...mp;yt0=Go!
Nasdaq stocks posting largest volume increases
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
After Yesterday's Rally of 21.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 12, 4:38PM CDT
Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $3.05 to a high of $3.47. Yesterday, the shares gained 21.1%, which took the trading range above the 3-day high of $2.77 on volume of 47.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Why Geron, Restoration Hardware, and ImmunoGen Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 4:15PM CDT
Today, in contrast to the past couple of days, investors had an absolute smorgasbord of economic data dropped in their laps; and the initial reaction is that they were none too impressed, with the S&P 500 suffering its worst single-day loss in... (full story)
Twitter and Delta are big market movers
AP - Thu Jun 12, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Jun 12, 1:43PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels. (full story)
Why Geron Corporation Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Geron , a clinical-stage biopharmaceutical... (full story)
Why Geron (GERN) Stock is Surging Today
at The Street - Thu Jun 12, 8:59AM CDT
Geron (GERN) surged Thursday after the company announced the FDA had removed a partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). (full story)
Geron Corp. (GERN) Soars: Stock Up 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:39AM CDT
Geron Corporation (GERN) was a big mover last session, as its shares rose over 10% on the day. (full story)
Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 12, 7:26AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation and Arena Pharmaceuticals . Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company... (full story)
Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST
Thomson Reuters ONE - Thu Jun 12, 4:00AM CDT
Menlo Park, Calif., June 12, 2014 - Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. In order to resolve the partial clinical hold, the investigator, Dr. Ayalew Tefferi of Mayo Clinic, Rochester, Minnesota, was required to provide follow-up information regarding reversibility of hepatotoxicity for all patients who received imetelstat in the Myelofibrosis IST. In its letter dated June 11, 2014, the FDA informed the investigator that it had completed the review of his complete response submission and concluded that the Myelofibrosis IST may proceed. (full story)
Stock to Watch: Geron Up 11.3% (GERN)
Comtex SmarTrend(R) - Wed Jun 11, 11:38AM CDT
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 11.3% to $2.62 on 3.1x average daily volume. Thus far today, Geron has traded 7.8 million shares, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (11.3% to the Dow's -0.5%) and outperformed the S&P 500 (11.3% to the S&P's -0.3%) during today's trading. (full story)
This Biotech Stock Could Be the Next Big Short Squeeze
at The Street - Tue Jun 10, 1:38PM CDT
The biotech sector is back in play on Wall Street in a big way, and anyone short the sector has to be feeling nervous (full story)
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron
PR Newswire - Fri May 30, 6:10AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average finished the day 0.39% higher at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, and the index has advanced 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) and Geron Corp. (NASDAQ: GERN). Free technical research on GILD, ARIA, RNN and GERN can be downloaded upon signing up at: (full story)
ViaCyte and Asterias Biotherapeutics Settle Patent Dispute
PR Newswire - Thu May 29, 8:00AM CDT
ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes, announced today that the Company has settled a patent dispute involving certain of the Company's definitive endoderm patents and patent applications. The dispute involved an appeal to the U.S. District Court by Asterias Biotherapeutics, Inc., (as assignee of Geron Corporation), which sought to overturn both decisions by the U.S. Patent and Trademark Office (USPTO) against Geron in its patent interferences. (full story)
Geron to Present at the Jefferies Healthcare Conference
Thomson Reuters ONE - Wed May 28, 6:31AM CDT
MENLO PARK, Calif., May 28, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Jefferies 2014 Global Healthcare Conference in New York. The presentation is scheduled to occur at 10:00 a.m. Eastern Time on Wednesday, June 4th. (full story)
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Tue May 27, 2:15PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long... (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu May 22, 1:33PM CDT
These under-$10 stocks look ready to trade higher from current levels. (full story)
Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
Business Wire - Wed May 21, 8:15AM CDT
Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX) that is developing clinical-stage stem cell therapeutic assets acquired from Geron Corporation, today announced the launch of its new website, www.asteriasbiotherapeutics.com. The website provides information about Asterias, including its core technologies, areas of product development focus, intellectual property portfolio, key publications, SEC filings, and management team. (full story)
(0)
(0)Geron Corporation (GERN) Stock Research Links
Scroll down for more posts ▼